Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE -/- mice by downregulating the HMGB1-RAGE axis

Acta Pharmacologica Sinica

Volumn 34, Issue 6, 2013, Pages 830-836

  Liu, Ming ^a   Yu, Ying ^a   Jiang, Hong ^a   Zhang, Lei ^a   Zhang, Pei Pei ^a   Yu, Peng ^a   Jia, Jian Guo ^a   Chen, Rui Zhen ^a   Zou, Yun Zeng ^a   Ge, Jun Bo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

aortic sinus; ApoE mice; atherosclerosis; HMGB1; human umbilical vein endothelial cells (HUVECs); inflammation; macrophages; MCP 1; RAGE; simvastatin; VCAM 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; STAINING; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS; WESTERN BLOTTING;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; DOWN-REGULATION; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; SIMVASTATIN;

EID: 84881463486     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.8     Document Type: Article

References (23)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60.
3. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24: 2320-5.
4. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 313-9.
5. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachidonatedependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070-7.
6. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-31.
7. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-35.
8. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008; 118: 183-94.
9. Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med 2005; 7: 459-66.
10. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 2010; 74: 818-26.
11. Yin YX, Yao YM, Liu RM, Zhai HX, Li L, Zhang JJ, et al. The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010; 22: 306-8.
12. Wang L, Zhang X, Liu L, Yang R, Cui L, Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 2010; 471: 152-6.
13. Haraba R, Suica VI, Uyy E, Ivan L, Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 2011; 346: 361-8.
14. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-23.
15. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008; 51: 1731-40.
16. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-21.
17. Baglione J, Smith JD. Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol Med 2006; 129: 83-95.
18. Baudin B, Bruneel A, Bosselut N, Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc 2007; 2: 481-5.
19. Nathan L, Pervin S, Singh R, Rosenfeld M, Chaudhuri G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis. Circ Res 1999; 85: 377-85.
20. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
21. Scaffidi P, Mistell T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
22. Li W, Sama AE, Wang H. Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 2006; 6: 130-5.
23. Yang J, Huang C, Yang J, Jiang H, Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2010; 345: 189-95.